Soluble biomarkers and morbidity and mortality among people infected with HIV: Summary of published reports from 1997 to 2010

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 480-490

  Neaton, James D ^a   Neuhaus, Jacqueline ^a   Emery, Sean ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biomarkers; clinical outcomes; literature review

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; HEMOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; HIV INFECTIONS; HUMANS; MORBIDITY; PROGNOSIS;

EID: 78049281808     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833ed75d     Document Type: Review

References (81)

1. Biomarker Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. IOM (Institute of Medicine). Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, District of Columbia, USA: The National Academies Press; 2010.
3. Medrano FJ, Leal F, Arienti D, et al. Tumor necrosis factor (and solubleAPO-1/Fas independently predict progression to AIDS in HIV-seropositive patients. AIDS Res Hum Retroviruses 1998; 14:835-843.
4. Zangerle R, Steinhuber S, Sarcletti N, et al. Serum HIV-RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol 1998; 116:226-239.
5. Fahey JL, Taylor JMG, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998; 12:1581-1590.
6. Ledergerber B, Flepp M, Boni J, et al. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparisons with viral RNA measurement. J Infect Dis 2000; 181:1280-1288.
7. Sidenius N, Sier CFM, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96:4091-4095.
8. Havlir DV, Torriani FJ, Schrier RD, et al. Serum interleukin-g (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol 2001; 39:298-303.
9. Lewden C, Raffi F, Cuzin L, et al. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and early transaminase level elevation (APROCO-ANRS EP 11 Study). J Infect Dis 2002; 186:710-714.
10. Sabin CA, Griffioen A, Yee TT, et al. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet 2002; 360:1546-1551.
11. Gardner LI, Holmberg SD, Williamson JM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:203-209.
12. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women with HIV infection. J Acquir Immune Defic Syndrome 2003; 32:210-214.
13. Ostrowski S, Gerstoft J, Pedersen BK, Ullum H. Impaired production of cytokines is an independent predictor of mortality in HIV-1 infected patients. AIDS 2003; 17:521-530.
14. Sipsas N, Sfikakis PP, Touloumi G, et al. Elevated serum levels of soluble immune activation markers are associated with increased risk of death in HAART-naïve HIV-1 infected patients. AIDS Patients Care STDs 2003; 17:147-153.
15. Feldman JG, Gange SJ, Bacchetti P, et al. Serum albumin is a powerful predictor of survival among HIV-1 infected women. J Acquir Immune Defic Syndrome 2003; 33:66-73.
16. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63:2084-2090.
17. Mildvan D, Sprizler J, Grossberg SE, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 2005; 40:853-858.
18. Ostrowski SR, Piironen T, Høyer-Hansen G, et al. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:23-31.
19. Jaffar S, Van der Loeff MS, Eugen-Olsen J, et al. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res Hum Retroviruses 2005; 21:560-564.
20. Brechtl JR, Patrick PA, Visintainer P, Brand DA. Predictors of death within six months in patients with advanced AIDS. Palliat Support Care 2005; 3:265-272.
21. Mehta SH, Astemborski J, Sterling TR, et al. Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses 2006; 22:14-21.
22. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker of human immunodeficiency virus disease progression. Arch Int Med 2006; 166:64-70.
23. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007; 64:97-102.
24. Lawn SD, Myer L, Bangani N, et al. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis 2007; 7:41.
25. Drain PK, Kupka R, Msamanga GI, et al. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS 2007; 1:2067-2075.
26. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-187.
27. El-Bejjani D, Hazen SL, Mackay W, et al. Higher plasma myeloperoxidase levels are not associated with an increased risk of cardiovascular events in HIV-infected adults. HIV Clin Trials 2008; 9:207-211.
28. Erikstrup C, Kallestrup P, Zinyama-Gutsire RBL, et al. p24 as a predictor of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr 2008; 48:345-349.
29. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
30. Morlat P, Pereira E, Clayette P, et al. Early evolution of plasma soluble TNF-a p75 receptor as a marker of progression in treated HIV-infected patients. AIDS Res Hum Retroviruses 2008; 24:1383-1389.
31. Rawat R, Humphrey JH, Ntozini R, et al. Elevated iron stores are associated with HIV disease severity and mortality among postpartum women in Zimbabwe. Pub Health Nutr 2008; 12:1321-1329.
32. McDermid JM, van der Loef MFS, Jaye A, et al. Mortality in HIV infection is independently predicted by host iron status and SLC11A1 and HP genotypes, with new evidence of a gene-nutrient interaction. Am J Clin Nutr 2009; 90:225-233.
33. Rodger AJ, FoxZ, Lundgren J, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-983.
34. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
35. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010; 11:143-151.
36. Kalayjian RC, Machekano RN, Nesrine R, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-1805.
37. Cockerham L, Scherzer R, Zolopa A, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr 2010; 53:102-106.
38. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collection on Adverse Effects of Anti-HIV Drugs Study. Euro J Cardiovasc Prev Rehabil 2010. [Epub ahead of print]
39. Tien PC, Choi AI, Zolopa Z, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM Study Cohort. J Acquir Immune Defic Syndr 2010. [Epub ahead of print]
40. Estrella MM, Parekh RS, Abraham A, et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 2010. [Epub ahead of print]
41. Duprez DA for the INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in the Strategies for Management of Anti-Retro-viral Therapy Study [abstract #P1031-124]. 58th Annual Scientific Session of the American College of Cardiology; 29-31 March 2009; Orlando, Florida, USA.
42. Ledwaba L, Maja P. Pre-ART plasma levels of inflammation and coagulation makers are strong predictors of death after commencing ART in a South African cohort with advanced HIV disease [abstract]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa.
43. Sandler N, Wand H, Nixon D, et al. Plasma levels of soluble CD14 predict mortality in HIV infection [abstract #303]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
44. Peters L for INSIGHT SMART Study Group. Biomarkers of inflammation and coagulation and risk of non-AIDS death (NAD) in HIV/hepatitis co-infected patients in the SMART study [abstract #660]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
45. Duprez DA for the INSIGHT SMART Study Group. N-terminal-proB-type natriuretic peptide (NT-proBNP) predicts cardiovascular disease events in HIV-infected patients: results of the SMART study [abstract #712]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
46. Boulware D, Huppler HullsiekK, Puronen C, et al. Higher levels of D-dimer, C-reactive protein, hyaluronic acid, and IL-6 before initiation of ART are associated with AIDS, IRIS and death among ART-naive patients with a good virologic response to initial ART [abstract #335]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
47. Ambinder R for the INSIGHT SMART Study Group. Biomarkers of angiogen-esis and gherpes viruses and the development of cancer in patients on episodic and continuous antiretroviral therapy in SMART [abstract #760]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
48. Ford E, Richterman A, Thompson W, et al. Elevated D-dimer but not CRP levels in HIV+ patients prior to incident myocardial infarction or other cardiovascular disease event [abstract #713]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
49. Worm S, Kamara A, El-Sadr W, et al. Triglycerides and the risk of myocardial infarction in the D:A:D study [abstract #127]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
50. Essebag V, Genest J, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003; 146:581-590.
51. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. Anty Engl J Med 1990; 322:166-172.
52. + T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993; 6:904-912.
53. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr 1997; 16:83-92.
54. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346-355.
55. Hazenberg MD, Otto SA, van Benthem BHB, et al. Persistent immune activation in HIV-1 infection associated with progression to AIDS. AIDS 2003; 17:1-8.
56. Catalfamo M, Di Mascio M, Hu Z, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci USA 2008; 105:19851-19856.
57. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality: an individual patient meta-analysis. Lancet 2010; 375:132-140.
58. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with morality in the elderly. Am J Med 1999; 106:506-512.
59. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
60. Luc G, Bard JM, Juhan-Vgue I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arter-ioscler Thromb Vasc Biol 2003; 23:1255-1262.
61. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunology 1990; 144:480-484.
62. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of Inflammation, coagulation and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
63. Johnson BD, Kip KE, Marrroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 726-732.
64. Jenny NS, Arnold AM, Kuller LH, et al. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2007; 27:352-358.
65. Danesh H, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103:2323-2327.
66. Cohen Hj, Harris T, Piper CF. Coagulation and activation of inflammatory pathways in the development of function decline and mortality in the elderly. Am J Med 2003; 114:180-187.
67. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-1809.
68. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829-1839.
69. Blake GJ, Otvos J, Rifai N, et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106:1930-1937.
70. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-1) trial. Am J Cardiol 2002; 90:89-94.
71. Danesh J, Collins R, Appleby P, Peto P. Fibrinogen, C-reactive protein, albumin and white cell count: meta-analysis of prospective studies of coronary heart disease. JAMA 1998; 279:1477-1482.
72. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
73. Schambelan M, Wilson PWF, Yarasheski KE, et al. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118:e48-e53.
74. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
75. Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148:337-347.
76. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150:795-802.
77. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100:1432-1438.
78. Phillips AN, Neaton J, Lundgren J. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
79. Fleming TR, DeMets DL Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-613.
80. + lympho-cytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
81. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000;16:1123-1133.